Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or New Mexico for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to New Mexico only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. New Mexico (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Ramadevi Medavarapu (NPI 1427298520)

Field	Value
Entity Type	Individual
Organization	Ramadevi Medavarapu
Address	4391 E Lohman Ave
City	Las Cruces
State	NM
ZIP	88011
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	March 2, 2009

Payer Source	Total Paid
Medicare	$1.5M
Medicaid	$0

Key Findings

This provider is effectively a Medicare-only practice: total Medicare revenue is $1.5M while there is no Medicaid billing on file. The absence of any Medicaid claims indicates the provider’s payer mix is concentrated on Medicare beneficiaries and commercial/other payers (if any), rather than state Medicaid programs, which has implications for network contracting and payment-risk exposure.

Revenue is highly concentrated in a small set of oncology drugs and high-intensity visits — the precomputed top 3 Medicare codes account for 83.6% of total Medicare revenue. In particular, J9271 (pembrolizumab) alone represents $997.6K or 65.7% of Medicare revenue, creating material dependence on one high-cost immunotherapy for practice revenue.

The clinical mix and code profile identify a community hematology/oncology infusion practice: large volumes of J9271 (23.2K claims) and J0897 (denosumab, 9.4K claims) plus chemotherapy administration codes like 96413 (571 claims) and supportive-agent billing (Q5108, 516 claims) indicate routine onsite delivery of systemic cancer therapy and related supportive care. These patterns align with a practice focused on office-based infusion of oncology biologics and cytotoxics rather than predominantly inpatient oncology consults.

Competitive standing for the practice’s top drug is above average but not uniquely dominant: J9271 ranks #274 of 1841 providers nationally (85th percentile) and is labeled “typical, unremarkable volume,” meaning the provider delivers high absolute pembrolizumab revenue ($997.6K) but sits in the upper-middle of national peers rather than among top few national centers. Similarly, J0897 ranks #1280 of 10057 (87th percentile; typical, unremarkable volume), so denosumab use is above typical but not exceptional.

There are striking statistical outliers in E/M coding intensity that suggest a heavier-than-typical case complexity or different visit mix: 99215 generates $102K (791 claims) and ranks #554 of 145531 providers nationally at the 100th percentile, described as an “extreme outlier, far above typical national volume.” The provider also reports 99205 (164 claims, $25.6K) at the 99th percentile (rank #729 of 66257; extreme outlier), indicating unusually high volumes of high-complexity new- and established-patient office encounters relative to national peers.

Chemotherapy administration codes show above-typical infusion activity: 96413 (571 claims, $53.7K) ranks #480 of 7514 providers (94th percentile; notably above typical national volume) and add-on infusion codes such as 96367 (960 claims, $20.2K) rank #86 of 4032 (98th percentile; notably above typical national volume). These data support that infusion throughput and multi-drug sessions are meaningful operational components of the practice.

The provider’s tenure is long-established: NPI enumerated 2009-03-02 (~17 years ago), indicating sustained enrollment in Medicare and likely an established referral base and operational infrastructure for oncology services. That longevity combined with the revenue and code mix suggests an entrenched outpatient oncology practice rather than a new or transient clinician.

From a business-risk and contracting perspective, the concentration in a single high-cost drug (J9271 at 65.7% of Medicare revenue) and the Medicare-only billing profile create both negotiating leverage and vulnerability: payers or reimbursement changes affecting pembrolizumab or chemotherapy infusion reimbursement could materially impact practice revenue, while the strong E/M intensity (extreme outlier status for 99215/99205) may support negotiation for higher visit-based rates or targeted utilization reviews by payers.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

38 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	23,200	$40	$997.6K
J0897	Injection, denosumab, 1 mg	9,360	$20	$168.5K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	790	$130	$102K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	570	$90	$53.7K
Q5108	Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg	520	$100	$49.5K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	340	$90	$29.9K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	160	$160	$25.6K
96367	The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose…	960	$20	$20.2K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	340	$60	$19.9K
96417	In this add–on procedure, the provider continues administration of a chemotherapy drug into a vein using an infusion technique. He uses this code to report administration of a different chemotherapy…	190	$50	$8.7K

Showing 1–10 of 38

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 38 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. New Mexico Distribution

Ramadevi Medavarapu — 13 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — New Mexico

Full comparison — all codes billed, vs. state median

38 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	1	10	9,400	$40	$469.6K
J0897	7	50	3,150	$20	$113.2K
Q5108	2	10	520	$90	$39.9K
96413	1	40	170	$90	$17.7K
J3490	10	20	40	$150	$16.7K
Q5110	1	10	52,800	$1	$13.4K
99214	359	2,700	90	$70	$12.9K
99215	4	960	40	$110	$7.8K
99213	235	2,440	60	$50	$7.3K
99223	287	490	30	$130	$7.3K

Showing 1–10 of 38

Related Providers

Other providers that share a Tax Identification Number (TIN) with Ramadevi Medavarapu, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Phc-las Cruces Inc	NM	General Acute Care Hospital	$0	$64.8M
John Pitcher	NM	Ophthalmology Physician	$5.1M	$0
Richard Kinsey	TN	Anatomic Pathology & Clinical Pathology Physician	$3.3M	$147.3K
Mark Carmichael	CA	Hematology & Oncology Physician	$3.1M	$0
Howard Martin	TX	Dermatopathology (Pathology) Physician	$3M	$0
Daniel Kasuga	TX	Retina Specialist (Ophthalmology) Physician	$2.9M	$0
Phc-las Cruces Inc	NM	Family Medicine Physician	$0	$2.7M
Richard Hwang	TX	Retina Specialist (Ophthalmology) Physician	$2.6M	$0
Cary Chisholm	TX	Anatomic Pathology & Clinical Pathology Physician	$2.5M	$24.7K
Joseph Furlong	TX	Diagnostic Radiology Physician	$2.4M	$39.7K

Nearby Providers

Other providers in the same ZIP code as Ramadevi Medavarapu, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mountain Shadows Home Care Services, Inc	NM	Home Health Agency	$0	$92.9M
Las Cruces Medical Center LLC	NM	General Acute Care Hospital	$0	$86.8M
Addus Healthcare, Inc.	NM	In Home Supportive Care Agency	$0	$81.1M
Las Cruces Physician Services LLC	NM	Orthopaedic Surgery Physician	$0	$62.9M
Multicultural Evaluation & Consultation Associates LLC	NM	Early Intervention Provider Agency	$0	$59.3M
Quality Life Services, LLC	NM	Specialist	$0	$44.9M
Las Cruces Physician Practices, LLC	NM	Family Medicine Physician	$0	$22.8M
Southwest Emergency Medical Associates Of Nm PC	NM	Emergency Medicine Physician	$0	$20.3M
Milagro De Vida Community Services LLC	NM	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$20.2M
Joseph B. Furlong, P.A.	NM	Specialist	$0	$14.4M

Ramadevi Medavarapu — Billing Profile & Reimbursement Data

Sign up for Ramadevi Medavarapu — Billing Profile & Reimbursement Data policy alerts

Ramadevi Medavarapu — Billing Profile & Reimbursement Data

Sign up for Ramadevi Medavarapu — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References